Foresite Capital Management IV, LLC — 13F Holdings & Portfolio
CIK 1704132 · latest 13F-HR filed 2026-05-15
Foresite Capital Management IV, LLC manages $237.1M in 13F-reported U.S. long-equity assets across 8 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PHVS (56.94%), CYTK (13.99%), EIKN (8.67%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 4, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$237.1M
Long-equity book
8
Distinct positions
2026-03-31
Filed 2026-05-15
+1 / −0 / ↑4 / ↓2
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- CYTOKINETICS INC$4.1M +13.9%
- Alector, Inc.$2.3M +37.8%
- Xenon Pharmaceuticals Inc.$2.1M +29.7%
- Relay Therapeutics, Inc.$1.5M +17.6%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | PHVS | N69605108 | $135.0M | 56.94% | 4,778,581 | SH |
| 2 | CYTOKINETICS INC | CYTK | 23282W605 | $33.2M | 13.99% | 503,295 | SH |
| 3 | Eikon Therapeutics, Inc. | EIKN | 282564103 | $20.6M | 8.67% | 1,943,682 | SH |
| 4 | Lyell Immunopharma, Inc. | LYEL | 55083R203 | $16.1M | 6.77% | 800,399 | SH |
| 5 | Relay Therapeutics, Inc. | RLAY | 75943R102 | $9.9M | 4.20% | 1,000,000 | SH |
| 6 | Xenon Pharmaceuticals Inc. | XENE | 98420N105 | $9.3M | 3.92% | 160,000 | SH |
| 7 | Alector, Inc. | ALEC | 014442107 | $8.4M | 3.53% | 3,887,200 | SH |
| 8 | Maze Therapeutics, Inc. | MAZE | 578784100 | $4.7M | 1.98% | 156,901 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $237.1M | 8 | 0001104659-26-062462 |
| 2025-12-31 | 2026-02-17 | $229.7M | 7 | 0001104659-26-015407 |
| 2025-09-30 | 2025-11-14 | $182.6M | 6 | 0001104659-25-112500 |